Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency

NCT02068521 is registered in ClinicalTrials.gov with Versartis Inc. as lead sponsor.

NCT NCT02068521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02068521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Lead sponsor
Versartis Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
March 3, 2014
Completion date
November 17, 2017
Enrollment
385 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric growth hormone deficiency